Advanced searches left 3/3

Engineering - BioProject

Summarized by Plex Scholar
Last Updated: 05 July 2022

* If you want to update the article please login/register

Simultaneous multifunctional transcriptome engineering by CRISPR RNA scaffold

Although targeted RNA engineering has become feasible with the development and engineering of the CRISPR-Cas13 device, simultaneous modification of various RNA processing steps remains difficult. gRNA wRNA engineering Scaffold Tagged gRNA, a novel platform that can simultaneously execute multiple RNA modification steps on various RNA targets. In CREST, RNA scaffolds are appended to the 3rd of Cas13 gRNA and their cognate RNA binding proteins are fused with enzymatic domains for modification. The CREST framework's flexibility will extend the transcriptome engineering toolbox for the study of RNA biology and the creation of RNA-focused therapeutics, as shown in the metadata. To determine the RNA editing off-target events at the transcriptome wide.

Source link: https://www.ncbi.nlm.nih.gov/bioproject/851969


DNASeq of different Mycoplasma pneumoniae isolated clones presenting a genomic deletion produced by a multi-recombinase engineering protocol

We performed whole genome sequencing of several clones to determine that the engineering method is not mutagenic and that genome changes only occurred at the intended loci. Specifically, we sequenced clones carrying 1 kb deletion at 4 distinct chromosomal locations, a clone carrying a 30 kb deletion, and a clone carrying a 5. 5 kb deletion that was complemented by the two primary genes present in this area.

Source link: https://www.ncbi.nlm.nih.gov/bioproject/840454


Orthogonal Gene Engineering Enables Novel Synthetic States of Powerful Tumor-rejecting CD8+ T Cells Escaping Canonical Exhaustion

Our research reveals that orthogonal gene-engineering of T cells to mask an IL-2-variant binding the IL-2R067 and the alarming IL-33. Our research leads to the first evidence that canonical exhaustion and demonstrated superior effector properties. During days 5–12, 12 and 26 post cell transfer TILs were independently classified by a group of non-Treated tumor-bearing mice; Mice were ACT using PD1d/IL2V-tested T cells; Mice were treated with ACT using PD1d/33-secretive OT1; and Mice were treated with ACT using PD1d/33-secretive OT1; Mice were treated with ACT.

Source link: https://www.ncbi.nlm.nih.gov/bioproject/825099

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions